Browse LBR

Summary
SymbolLBR
Namelamin B receptor
Aliases DHCR14B; TDRD18; tudor domain containing 18; LMN2R; PHA; integral nuclear envelope inner membrane protein; L ......
Chromosomal Location1q42.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus inner membrane; Multi-pass membrane protein.
Domain PF01222 Ergosterol biosynthesis ERG4/ERG24 family
PF09465 Lamin-B receptor of TUDOR domain
Function

Anchors the lamina and the heterochromatin to the inner nuclear membrane.

> Gene Ontology
 
Biological Process GO:0006066 alcohol metabolic process
GO:0006694 steroid biosynthetic process
GO:0006695 cholesterol biosynthetic process
GO:0008202 steroid metabolic process
GO:0008203 cholesterol metabolic process
GO:0016125 sterol metabolic process
GO:0016126 sterol biosynthetic process
GO:0044283 small molecule biosynthetic process
GO:0046165 alcohol biosynthetic process
GO:1901615 organic hydroxy compound metabolic process
GO:1901617 organic hydroxy compound biosynthetic process
GO:1902652 secondary alcohol metabolic process
GO:1902653 secondary alcohol biosynthetic process
Molecular Function GO:0005521 lamin binding
GO:0016627 oxidoreductase activity, acting on the CH-CH group of donors
GO:0016628 oxidoreductase activity, acting on the CH-CH group of donors, NAD or NADP as acceptor
GO:0050613 delta14-sterol reductase activity
GO:0070087 chromo shadow domain binding
Cellular Component GO:0005635 nuclear envelope
GO:0005637 nuclear inner membrane
GO:0005639 integral component of nuclear inner membrane
GO:0031229 intrinsic component of nuclear inner membrane
GO:0031300 intrinsic component of organelle membrane
GO:0031301 integral component of organelle membrane
GO:0031965 nuclear membrane
GO:0044453 nuclear membrane part
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-191273: Cholesterol biosynthesis
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
Summary
SymbolLBR
Namelamin B receptor
Aliases DHCR14B; TDRD18; tudor domain containing 18; LMN2R; PHA; integral nuclear envelope inner membrane protein; L ......
Chromosomal Location1q42.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LBR and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolLBR
Namelamin B receptor
Aliases DHCR14B; TDRD18; tudor domain containing 18; LMN2R; PHA; integral nuclear envelope inner membrane protein; L ......
Chromosomal Location1q42.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LBR in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.6 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolLBR
Namelamin B receptor
Aliases DHCR14B; TDRD18; tudor domain containing 18; LMN2R; PHA; integral nuclear envelope inner membrane protein; L ......
Chromosomal Location1q42.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LBR in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0190.943
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1130.951
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0490.971
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0620.849
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1190.95
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0120.996
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2880.485
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0140.994
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.6650.717
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5680.692
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.720.741
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0580.388
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LBR in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.407.40.0709
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.407.40.096
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512200200.294
Summary
SymbolLBR
Namelamin B receptor
Aliases DHCR14B; TDRD18; tudor domain containing 18; LMN2R; PHA; integral nuclear envelope inner membrane protein; L ......
Chromosomal Location1q42.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LBR. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLBR
Namelamin B receptor
Aliases DHCR14B; TDRD18; tudor domain containing 18; LMN2R; PHA; integral nuclear envelope inner membrane protein; L ......
Chromosomal Location1q42.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LBR. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LBR.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLBR
Namelamin B receptor
Aliases DHCR14B; TDRD18; tudor domain containing 18; LMN2R; PHA; integral nuclear envelope inner membrane protein; L ......
Chromosomal Location1q42.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LBR. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLBR
Namelamin B receptor
Aliases DHCR14B; TDRD18; tudor domain containing 18; LMN2R; PHA; integral nuclear envelope inner membrane protein; L ......
Chromosomal Location1q42.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LBR expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLBR
Namelamin B receptor
Aliases DHCR14B; TDRD18; tudor domain containing 18; LMN2R; PHA; integral nuclear envelope inner membrane protein; L ......
Chromosomal Location1q42.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LBR and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLBR
Namelamin B receptor
Aliases DHCR14B; TDRD18; tudor domain containing 18; LMN2R; PHA; integral nuclear envelope inner membrane protein; L ......
Chromosomal Location1q42.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LBR collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.